Next 10 |
Shares of ArTara to commence trading on Nasdaq under new ticker symbol “TARA” effective January 10, 2020 Company completes previously announced equity financing of $42.5 million concurrently with the closing of the merger Combined company will focus on developing tre...
NEW YORK , Dec. 3, 2019 /PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located on Wall Street in downtown New York City , is investigating potential claims involving the directors and officers regarding possible breaches of fiduciary duties and other violations of law related t...
NEW YORK , Nov. 22, 2019 /PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located on Wall Street in downtown New York City , is investigating potential claims involving the directors and officers regarding possible breaches of fiduciary duties and other violations of law rel...
Proteon Therapeutics (NASDAQ: PRTO ): Q3 GAAP EPS of -$0.08 beats by $0.01 . More news on: Proteon Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
WALTHAM, Mass., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Proteon Therapeutics, Inc. (“Proteon” or the “Company”) (Nasdaq: PRTO), a company that has historically focused on the development of novel, first-in-class pharmaceuticals to address the medical needs of patie...
NEW YORK , Sept. 25, 2019 /PRNewswire/ -- Bragar Eagel & Squire, P.C. is investigating potential claims against the board of directors of Proteon Therapeutics, Inc. (NASDAQ: PRTO) on behalf of Proteon shareholders concerning the proposed merger with ArTara Therapeutics, Inc. ...
NEW YORK, Sept. 24, 2019 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, a global investor rights law firm, is investigating the following companies: Proteon Therapeutics, Inc. (NASDAQ: PRTO ) The investigation concerns whether Proteon and its board of directors violated the federal securitie...
Proteon Therapeutics (NASDAQ: PRTO ) and privately held ArTara Therapeutics have agreed to a tie-up in a reverse merger transaction after which the combined company will do business under the ArTara name. Shares will trade under the ticker "TARA." More news on: Proteon Therapeutics, Inc....
Transaction to Create NASDAQ-Listed Rare and Specialty Disease Therapeutic Company Focused on Immunology and Metabolic Disorders $42.5M Concurrent Financing to be Led by a Syndicate of Healthcare Dedicated Investors Companies to Hold Conference Call on September 24 th at 8:30AM ED...
Proteon Therapeutics (NASDAQ: PRTO ): Q2 GAAP EPS of -$0.27 misses by $0.14 . More news on: Proteon Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Proteon Therapeutics Inc. Company Name:
PRTO Stock Symbol:
NASDAQ Market:
Proteon Therapeutics Inc. Website:
Shares of ArTara to commence trading on Nasdaq under new ticker symbol “TARA” effective January 10, 2020 Company completes previously announced equity financing of $42.5 million concurrently with the closing of the merger Combined company will focus on developing tre...
NEW YORK , Dec. 3, 2019 /PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located on Wall Street in downtown New York City , is investigating potential claims involving the directors and officers regarding possible breaches of fiduciary duties and other violations of law related t...
NEW YORK , Nov. 22, 2019 /PRNewswire/ -- Moore Kuehn, PLLC, a securities law firm located on Wall Street in downtown New York City , is investigating potential claims involving the directors and officers regarding possible breaches of fiduciary duties and other violations of law rel...